NOVEL SIMPLE SCREEN FOR POTASSIUM CHANNELS
NOVEL SIMPLE SCREEN FOR POTASSIUM CHANNELS
批准号:
2643512
负责人:
Antonio E. Lacerda
金额:
$8.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-01 至 1999-08-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from the application): Chan Test Inc. is a drug
testing company that provides customized contract services for lead
screening of ion channels. Based on their experience over the past three
years Chan Test has developed successful protocols that meet the unique
needs of each of their customers. Because their protocols and contract
services are now established for lead screening and because the
pharmaceutical industry is very interested in voltage-dependent K+ (Kv)
channels as targets for development of new drugs, the time is ripe to
develop a novel high throughput screen for these channels. This
additional capability will extend their range of services and enhance
their lead screening business in two ways, first by increasing their
client base and second by providing more candidate drugs for lead
screening. Kv channels are therapeutic targets for cardiac arrhythmias,
stroke, hypertension heart failure, asthma, diabetes, irritable colon,
gastro-esophageal reflux disorders, urinary incontinence, epilepsy,
migraine and neuropsychiatric disorders. In this Phase I SBIR they will
test the feasibility of a novel, simple screen that they are developing
using genetic engineering of a protist species. The innovative feature is
that the species will be dependent for growth on extracellular K+
concentrations that will also activate Kv channels. The readout is
simple: growth or no growth. The effects of the genetic engineering will
be monitored by Southern analysis and electrophysiological recording of
membrane currents. The channels to be examined initially will be the
Human Ether-A-GO-GO related Gene (HERG) product and as a control, the
human inwardly rectifying K+ channel Kir 2.2. HERG was selected because it
is: 1) critical to cardiac repolarization, 2) the main target for class
III cardiac antiarrhythmic drugs, and 3) mutated in hereditary along QT
syndrome. Other Kv channels will be tested subsequently. In Phase II
they will implement the high throughput features of the screen.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New drugs for treatment of atrial fibrillation
-
批准号:6755989
-
项目类别:
-
资助金额:$20.06万
-
财政年份:2001
-
负责人:Antonio E. Lacerda
-
依托单位:
New drugs for treatment of atrial fibrillation
-
批准号:6587508
-
项目类别:
-
资助金额:$37.98万
-
财政年份:2001
-
负责人:Antonio E. Lacerda
-
依托单位:
New drugs for treatment of atrial fibrillation
-
批准号:6337525
-
项目类别:
-
资助金额:$9.99万
-
财政年份:2001
-
负责人:Antonio E. Lacerda
-
依托单位:
KINETICS OF CA CHANNELS IN CULTURED CELLS
-
批准号:3050151
-
项目类别:
-
资助金额:$2.6万
-
财政年份:1987
-
负责人:Antonio E. Lacerda
-
依托单位:
KINETICS OF CA CHANNELS IN CULTURED CELLS
-
批准号:3050152
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1986
-
负责人:Antonio E. Lacerda
-
依托单位:
KINETICS OF CA CHANNELS IN CULTURED CELLS
-
批准号:3050150
-
项目类别:
-
资助金额:$2.0万
-
财政年份:1985
-
负责人:Antonio E. Lacerda
-
依托单位:
海外基金